Brief: TetraLogic to proceed with expansion phase of study in patients with ovarian cancer

Tetralogic Pharmaceuticals

16/12/2014 12:00

Dec 16 (Reuters) - TetraLogic Pharmaceuticals Corp  TLOG.O : 
 * Provides update on ovarian cancer study 
 * Says intends to proceed with the expansion phase of its study in patients 
   with ovarian cancer 
 * Says following a review of the data with the investigators, the 
   recommendation is to continue the study 
 * Says to reduce the dose of birinapant and to limit dosing to 3 weeks out of 4 
 * Says intends to continue the study until approximately thirty patients have 
   been enrolled 
 
* Source text for Eikon  ID:nGNXVCIBZa  
 
* Further company coverage  TLOG.O  ((Bengaluru Newsroom; +1 646 223 8780))